NASDAQ: DHDefinitive Healthcare Corp Stock
$2.58+0.30 (+13.16%)
Updated Dec 18, 2025
DH Price
$2.58
Fair Value Price
N/A
Market Cap
$365.46M
52 Week Low
$2.15
52 Week High
$5.68
P/E
-1.54x
P/B
1.28x
P/S
1.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$242.28M
Earnings
-$188.69M
Gross Margin
75.9%
Operating Margin
-79.48%
Profit Margin
-77.9%
Debt to Equity
1.28
Operating Cash Flow
$59M
Beta
1.38
Next Earnings
Feb 19, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DH Overview
Definitive Healthcare Corp. offers business development and marketing support to help its customers optimize product development, go-to-market planning, and sales and marketing execution. Its platform offers 16 modules covering sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. Definitive Healthcare was founded in 2011 and is headquartered in Framingham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DH's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
DH
Ranked#5 of 44
Ranked#5 of 44
Be the first to know about important DH news, forecast changes, insider trades & much more!
DH News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DH is good value based on its book value relative to its share price (1.28x), compared to the US Health Information Services industry average (3.89x)
P/B vs Industry Valuation
DH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DH due diligence checks available for Premium users.
Valuation
DH fair value
Fair Value of DH stock based on Discounted Cash Flow (DCF)
Price
$2.58
Fair Value
$10.11
Undervalued by
74.49%
DH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.54x
Industry
43.27x
Market
44.14x
DH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.28x
Industry
3.89x
DH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DH's financial health
Profit margin
Revenue
$60.0M
Net Income
-$14.8M
Profit Margin
-24.7%
DH's Earnings (EBIT) of -$192.56M... subscribe to Premium to read more.
Interest Coverage Financials
DH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$755.5M
Liabilities
$365.9M
Debt to equity
1.28
DH's short-term assets ($246.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DH's short-term assets ($246.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$15.7M
Investing
$24.1M
Financing
-$12.5M
DH's operating cash flow ($59.19M)... subscribe to Premium to read more.
Debt Coverage Financials
DH vs Health Information Service Stocks
Definitive Healthcare Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.